CRISPR Therapeutics AG CRSP
NASDAQ
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 24.44% | 598.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 24.44% | 598.29% | |||
| Cost of Revenue | 5.35% | -6.20% | |||
| Gross Profit | -3.35% | 13.99% | |||
| SG&A Expenses | 1.79% | 2.15% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.85% | -5.11% | |||
| Operating Income | -3.11% | 11.86% | |||
| Income Before Tax | -23.47% | 26.13% | |||
| Income Tax Expenses | -92.29% | 14.42% | |||
| Earnings from Continuing Operations | -22.25% | 25.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -22.25% | 25.85% | |||
| EBIT | -3.11% | 11.86% | |||
| EBITDA | -3.27% | 12.24% | |||
| EPS Basic | -21.96% | 26.20% | |||
| Normalized Basic EPS | -13.36% | 28.49% | |||
| EPS Diluted | -21.96% | 26.21% | |||
| Normalized Diluted EPS | -13.36% | 28.49% | |||
| Average Basic Shares Outstanding | 0.24% | 0.48% | |||
| Average Diluted Shares Outstanding | 0.24% | 0.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||